Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 17/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18029669 | 0.84 | NLRP3 (0.53) | ATMSMN1; SMN2NLRP3ALDH1A1 | |
| Potassium SCHEMBL29676171 | 0.83 | NLRP3 (0.51) | ATMSMN1; SMN2NLRP3ALDH1A1 | |
| SCHEMBL29494713 | 0.83 | NLRP3 (0.51) | ATMSMN1; SMN2NLRP3ALDH1A1 | |
| SCHEMBL25845405 | 0.83 | NLRP3 (0.51) | ATMSMN1; SMN2NLRP3ALDH1A1 | |
| SCHEMBL22012162 | 0.81 | NLRP3 (0.50) | ATMSMN1; SMN2NLRP3ALDH1A1 | |
| SCHEMBL23674483 | 0.73 | ACHE (0.31) | — | |
| SCHEMBL20692209 | 0.72 | NLRP3 (0.45) | ATMSMN1; SMN2NLRP3ALDH1A1 | |
| SCHEMBL22012974 | 0.72 | NLRP3 (0.46) | ATMSMN1; SMN2NLRP3ALDH1A1 | |
| SCHEMBL30852987 | 0.70 | NLRP3 (0.63) | ATMSMN1; SMN2NLRP3ALDH1A1 | |
| SCHEMBL21646624 | 0.70 | NLRP3 (0.47) | ATMSMN1; SMN2NLRP3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159555-A1 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | GENENTECH, INC. (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159555-A1 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | ATM 1651/4885SMN1; SMN2 1849/4885NLRP3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.